OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2017年 / 7卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1061 / 1061
页数：1
相关论文
共 50 条
  • [21] Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression
    White, Maya N.
    Piotrowska, Zofia
    Stirling, Kevin
    Liu, Stephen V.
    Banwait, Mandeep K.
    Cunanan, Kristen
    Sequist, Lecia V.
    Wakelee, Heather A.
    Hausrath, Daniel
    Neal, Joel W.
    CLINICAL LUNG CANCER, 2021, 22 (03) : 201 - 209
  • [22] Osimertinib Called "Home Run" for EGFR-Mutant NSCLC
    Rose, Suzanne
    CANCER DISCOVERY, 2020, 10 (07) : 896 - 897
  • [23] Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy
    Luo, F.
    Liu, Y. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S672
  • [24] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
    Shreeve, S. M.
    Martinez, M.
    Verheijen, R. B.
    Xie, J.
    Sun, T.
    Haddish-Berhane, N.
    Curtin, J. C.
    Karkera, J.
    Pang, D.
    Roshak, A.
    Knoblauch, R. E.
    Patel, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
  • [25] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
    Smit, E. F.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
  • [26] Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers Reply
    Schoenfeld, Adam J.
    Yu, Helena A.
    JAMA ONCOLOGY, 2020, 6 (12) : 1983 - 1983
  • [27] Resolving Resistance to Osimertinib by Combining Apatinib and Osimertinib in EGFR-Mutant NSCLC Patients
    Yang, X.
    Zhao, J.
    Liang, L.
    Xu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S559 - S559
  • [28] Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment
    Corassa, Marcelo
    Abreu, Rodrigo Fonseca
    Cordeiro de Lima, Vladmir Claudio
    Torrezan, Giovana Tardim
    Cavalher, Felicia Peterson
    Silva, Tullio Novaes
    de Oliveira, Thiago Bueno
    Freitas, Helano Carioca
    Carraro, Dirce Maria
    Costa, Felipe D'Almeida
    JCO PRECISION ONCOLOGY, 2022, 6
  • [29] Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib
    Wu, Jia-Jun
    Tseng, Jeng-Sen
    Zheng, Zhe-Rong
    Chu, Cheng-Hsiang
    Chen, Kun-Chieh
    Lin, Mong-Wei
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Yang, Tsung-Ying
    Yu, Sung-Liang
    Chen, Jin-Shing
    Ho, Chao-Chi
    Chang, Gee-Chen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [30] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
    Tamura, Tomoki
    Hotta, Katsuyuki
    Gotoda, Hiroko
    Kato, Yuka
    Ichihara, Eiki
    Kubo, Toshio
    Tanimoto, Mltsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345